Hangzhou Hekang Pharmaceutical Co., Ltd.

To investigate the pharmacokinetic characteristics of a single oral dose of minocycline hydrochloride capsule [test preparation T, strength: 100 mg (calculated as C23H27N3O7)] provided by Hangzhou Hekang Pharmaceutical Co., Ltd. in healthy subjects under fasting and postprandial conditions and a single oral dose of minocycline hydrochloride capsule [reference preparation R, trade name: MINOMYCIN®, strength: 100 mg (calculated as C23H27N3O7)] certified by Pfizer Japan Inc. under the same conditions, and to evaluate the bioequivalence and safety of the two preparations.

This study aimed to investigate the pharmacokinetic characteristics of oxcarbazepine tablets (0.3 g) developed and produced by Hangzhou Hekang Pharmaceutical Co., Ltd. after single oral administration on an empty stomach or after a meal; using oxcarbazepine tablets (Trilep®, 0.3 g) produced by Novartis Farma S.p.A. as the reference preparation, the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared, and the bioequivalence of the two preparations in humans was evaluated.

Primary objective To compare the differences in the extent and rate of absorption of safinamide mesylate tablets (100 mg) provided by Hangzhou Hekang Pharmaceutical Co., Ltd. and safinamide mesylate tablets (100 mg, trade name: Xadago®) certified by Zambon S.p.A. in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary objective To evaluate the safety of safinamide mesylate tablets (100 mg) provided by Hangzhou Hekang Pharmaceutical Co., Ltd. and safinamide mesylate tablets (100 mg, trade name: Xadago®) certified by Zambon S.p.A. in healthy adults under fasting and postprandial administration conditions.